AU2014320474A1 - Pidotimod for use in the treatment of inflammation-associated diseases - Google Patents
Pidotimod for use in the treatment of inflammation-associated diseases Download PDFInfo
- Publication number
- AU2014320474A1 AU2014320474A1 AU2014320474A AU2014320474A AU2014320474A1 AU 2014320474 A1 AU2014320474 A1 AU 2014320474A1 AU 2014320474 A AU2014320474 A AU 2014320474A AU 2014320474 A AU2014320474 A AU 2014320474A AU 2014320474 A1 AU2014320474 A1 AU 2014320474A1
- Authority
- AU
- Australia
- Prior art keywords
- pidotimod
- physiologically acceptable
- stereoisomers
- acceptable salts
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title claims abstract description 76
- 229960001163 pidotimod Drugs 0.000 title claims abstract description 76
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 20
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 20
- 201000010099 disease Diseases 0.000 title claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 230000001363 autoimmune Effects 0.000 claims abstract description 10
- 208000026935 allergic disease Diseases 0.000 claims abstract description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 8
- 230000000172 allergic effect Effects 0.000 claims abstract description 8
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 8
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
- 230000037361 pathway Effects 0.000 claims abstract description 8
- 230000001594 aberrant effect Effects 0.000 claims abstract description 7
- 230000007246 mechanism Effects 0.000 claims abstract description 7
- 230000037417 hyperactivation Effects 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 10
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 9
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 9
- 239000012669 liquid formulation Substances 0.000 claims description 8
- 206010012442 Dermatitis contact Diseases 0.000 claims description 6
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 6
- 208000010247 contact dermatitis Diseases 0.000 claims description 6
- 206010043207 temporal arteritis Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 3
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000003782 Raynaud disease Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 3
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims description 3
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000004631 alopecia areata Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 claims description 3
- 208000001974 autoimmune enteropathy Diseases 0.000 claims description 3
- 201000004339 autoimmune neuropathy Diseases 0.000 claims description 3
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 claims description 3
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 claims description 3
- 208000029407 autoimmune urticaria Diseases 0.000 claims description 3
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 3
- 208000024376 chronic urticaria Diseases 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 208000005252 hepatitis A Diseases 0.000 claims description 3
- 208000002557 hidradenitis Diseases 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 21
- 102000002689 Toll-like receptor Human genes 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 230000002757 inflammatory effect Effects 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 108091005686 NOD-like receptors Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000012064 NLR Proteins Human genes 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 description 3
- 101710084317 NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 101150113790 nlr gene Proteins 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000730 protein immunoprecipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.
Description
WO 2015/036370 PCT/EP2014/069103 TITLE Pidotimod for use in the treatment of inflammation-associated diseases. The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune. BACKGROUND The recognition of microbial components during host infection is a key step in activating the innate immune response followed by the induction of inflammatory gene expression. Pattern-recognition receptors exemplified by toll like receptors (TLRs) are key regulators in host response to bacterial, viral and fungal components. Central to this response is the ability to up-regulate genes involved in host protection, innate and adaptive immune cell recruitment and pathogen clearance. Although the TLR-mediated inflammatory response is critical for providing immune defense against pathogens, dysfunctional responses may lead to both acute and chronic inflammatory states manifested as sepsis, inflammation and autoimmunity. Therefore, the intensity and duration of TLR responses must be tightly controlled (Lord et al. 2009). In addition to TLR, recent research has focused on the discovery and characterization of a new immune gene family, known as CATERPILLER or NOD-like receptor. Mutations in several NLR genes have been associated with human disease states, including autoimmunity and inflammation. Members of the NLR gene family are involved in regulating cellular activation after exposure to specific or multiple pathogen-derived products, NLR genes are involved in regulating a variety of host defense processes. The relevance of NLR genes is 1 WO 2015/036370 PCT/EP2014/069103 most apparently revealed by the genetic analysis of patients suffering from immune and inflammatory disorders (Lord et al. 2009). Monarch-1, also called "NOD-like receptor, pyrin domain containing 12" (NLRP12), is the best known component of NLRs. NLRP12 functions as a negative regulator of TLR- and TNFR-induced NF-KB signaling in human cells. NLRP12 blocks IRAK (IL-1R-associated kinase)-1 hyperphosphorylation/ activation and facilitates the degradation of NF-KB-inducing kinase (NIK), leading to reduced NF-KB activation (Lich et al. 2007). The result of the TLR-activated NF-KB signaling is the production of several inflammatory cytokines, including TNF-a. The overproduction of those cytokines leads to signs and symptoms of inflammatory diseases like allergies, autoimmune diseases and other acute/chronic inflammatory diseases. The most important diseases which are associated to an aberrant hyperactivation of the non canonical NF-kB pathway are summarized as follows (from Imani Fooladi et al. 2013; Delunardo et al. 2013; Meneghini et al. 2013; Lv et al. 2013; Monaco et al. 2004; Zhang et al. 2013; Medeiros, LaFerla. 2013; Qu et al. 2012; Wenhong et al. 2012; Qi et at. 2012; Mori T et al. 2012)): " Allergic diseases, like Allergic rhinitis, Allergic conjunctivitis, Atopic allergy, Atopic dermatitis, Contact dermatitis, Eczema and/or Allergic vasculitis. * Autoimmune diseases, like Alopecia areata, Ankylosing Spondylitis, Autoimmune cardiomyopathy, Autoimmune connective tissue diseases, Autoimmune enteropathy, Autoimmune hepatitis, Autoimmune peripheral neuropathy, Autoimmune pancreatitis, Autoimmune polyendocrine syndrome, Autoimmune thrombocytopenic purpura, Autoimmune urticaria, Autoimmune uveitis, Celiac disease, Chronic Fatigue Syndrome, Cystic fibrosis, Hashimoto's thyroiditis, Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura, IgA nephropathy, Juvenile idiopathic arthritis (or Juvenile rheumatoid arthritis, or Still's disease) Kawasaki's disease, Lichen planus, Lupus erythematosus, Rheumatoid arthritis, Rheumatic fever, 2 WO 2015/036370 PCT/EP2014/069103 Sj6gren's syndrome, Spondyloarthropathy, Temporal arteritis (or giant cell arteritis), Ulcerative colitis, Urticarial vasculitis, Vitiligo. Inflammatory diseases other than allergic or autoimmune, like Alzheimer's disease, Atherosclerosis, Chronic Liver Diseases, Chronic Nephropathy, Gastritis, Glomerulonephritis, Hepatitis A B & C, Hydradenitis suppurativa, Hypogammaglobulinemia, Interstitial cystitis, Lichen sclerosus, Liver steatosis, Metabolic Syndrome, Obesity, Parkinson's disease, Pemphigus vulgaris, Post-ischemic inflammation, Psoriasis, Psoriatic arthritis, Raynaud phenomenon, Restless leg syndrome, Retroperitoneal fibrosis, Thrombocytopenia. Pidotimod, whose chemical name is (4R)-3-(5-oxo-L-prolyl)-1,3-thiazolidine-4 carboxylic acid, was disclosed for the first time in IT1231723. It is a synthetic peptide-like molecule provided with an in vitro and in vivo immunomodulating action (Giagulli et al., 2009). Immune system intervenes in maintaining a homeostatic balance between our body and all foreign substances; therefore, an abnormality in this function may cause a defective or aberrant response towards non-self structures, as well as loss of tolerance toward self-antigens: in any cases, the immune system error exhibits clinically as signs of disease. Pidotimod exerts a protective action towards infectious processes (although it is free from a direct antimicrobial and antiviral action), as it has been confirmed in experimental bacterial and viral infection models and confirmed by a number of controlled clinical trials. Particularly, ex vivo studies highlighted the Pidotimod ability to increment phagocytes stimulation and relative phagocyte action, as well as the cytotoxic action of NK cells. Moreover, Pidotimod was found to increment the release of antiviral molecules (IFN-a) induced by specific stimuli (Taramelli et al. 1994). Pidotimod, administered in tablets via oral route, proved to be able to induce a higher resistance to viral infections in animal models, as well as a higher 3 WO 2015/036370 PCT/EP2014/069103 efficiency in the treatment of recurrent respiratory infections in the pediatric patients. DESCRIPTION OF THE INVENTION It has been now surprisingly found that, besides being active in sustaining protective antimicrobial immune responses Pidotimod increases transcription and synthesis of the NLRP12 (Monarch 1), involved in the control of inflammation consequent to TLR activation. This Pidotimod-induced event leads to the control of production of inflammatory mediators released by immune cells upon TLR stimulation. Therefore, through this newly discovered mechanism, Pidotimod is also able to mitigate the inflammatory pathway underlying inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, where NLRP12 plays a crucial role. The available drug therapy acts on the late effectors of the inflammatory cascade, e.g. by binding the TNFa or by reducing its concentrations, like the monoclonal antibodies, or by suppressing the immune system like corticosteroids, which is the cause of a number of untoward effects after prolonged use. On the contrary, by activating Monarch-1, Pidotimod is the only drug that acts at the very early stages of the inflammatory mechanism, switching off the cascade of NF-KB activation. Compared to monoclonal antibodies, its effect is much more general and not directed onto a single inflammatory cytokine. Compared to corticosteroids, pidotimod is extremely safe and does not induce the well known toxic effects of the long term cortisone therapy. The object of the present invention is therefore represented by the use of pidotimod, or its stereoisomers and/or a physiologically acceptable salts thereof, in the treatment of inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, such as allergic 4 WO 2015/036370 PCT/EP2014/069103 diseases, autoimmune diseases and other inflammatory diseases based on mechanisms different from allergic or autoimmune. The allergic diseases which can be treated in accordance to the present invention may be selected from Allergic rhinitis, Allergic conjunctivitis, Atopic allergy, Atopic dermatitis, Contact dermatitis, Eczema and/or Allergic vasculitis. The autoimmune diseases which can be treated in accordance to the present invention may be selected Alopecia areata, Ankylosing Spondylitis, Autoimmune cardiomyopathy, Autoimmune connective tissue diseases, Autoimmune enteropathy, Autoimmune hepatitis, Autoimmune peripheral neuropathy, Autoimmune pancreatitis, Autoimmune polyendocrine syndrome, Autoimmune thrombocytopenic purpura, Autoimmune urticaria, Autoimmune uveitis, Celiac disease, Chronic Fatigue Syndrome, Cystic fibrosis, Hashimoto's thyroiditis, Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura, IgA nephropathy, Juvenile idiopathic arthritis (or Juvenile rheumatoid arthritis, or Still's disease) Kawasaki's disease, Lichen planus, Lupus erythematosus, Rheumatoid arthritis, Rheumatic fever, Sjbgren's syndrome, Spondyloarthropathy, Temporal arteritis (or giant cell arteritis), Ulcerative colitis, Urticarial vasculitis, Vitiligo. The inflammatory diseases based on mechanisms different from allergic or autoimmune which can be treated in accordance to the present invention may be selected from Alzheimer's disease, Atherosclerosis, Chronic Liver Diseases, Chronic Nephropathy, Gastritis, Glomerulonephritis, Hepatitis A B & C, Hydradenitis suppurativa, Hypogammaglobulinemia, Interstitial cystitis, Lichen sclerosus, Liver steatosis, Metabolic Syndrome, Obesity, Parkinson's disease, Pemphigus vulgaris, Post-ischemic inflammation, Psoriasis, Psoriatic arthritis, Raynaud phenomenon, Restless leg syndrome, Retroperitoneal fibrosis, Thrombocytopenia. 5 WO 2015/036370 PCT/EP2014/069103 For the treatment of the present invention, pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, may be administered either systemically or topically. When administered systemically, it may be in the form of solid or liquid formulations containing pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, together with at least a pharmaceutically acceptable excipient and/or adjuvant; such formulations may be administered by parenteral (i.e., intramuscular or intravenous) route, by enteral (i.e., oral or rectal) route, in the customary formulations suitable for administration by the different routes. Such solid formulations to be systemically administered may have a w/w concentration in pidotimod from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%. Such liquid formulations to be systemically administered may have a w/w concentration in pidotimod from 0.5% to 20%, more preferably from 1% to 10%, most preferably from 2% to 8%. According to an embodiment of the invention, when administered orally, the amount of pidotimod, or of its stereoisomers and/or physiologically acceptable salts thereof, may vary from 10 to 1000 mg per single dose, more preferably from 50 to 800 mg per single dose. When administered topically, it may be in the form of solid, semisolid or liquid formulations containing pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, together with at least a pharmaceutically acceptable excipient and/or adjuvant; such formulations may be administered by dermal, ocular, auricular, nasal, buccal, intrasinal, endotracheal, vaginal, intravesical, rectal route, in the customary formulations suitable for administration by the different routes. 6 WO 2015/036370 PCT/EP2014/069103 Such semi-solid or liquid formulations to be topically administered may have a w/w concentration in pidotimod from 0.1% to 30%, more preferably from 1% to 20%, most preferably from 5% to 15%. Such solid formulations to be topically administered may have a w/w concentration in pidotimod from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%. The solid, semi-solid or liquid formulations to be used in accordance to the present invention may be prepared according to conventional techniques, may contain pharmaceutically acceptable excipients, adjuvants and/or carriers, and may also contain, in combination, one or more active principles with complementary or, in any case, useful activity. The pharmaceutical compositions and the uses of the present invention will now be more fully described by the following examples. It should, however, be noted that such examples are given by way of illustration and not of limitation. EXAMPLE 1 Pidotimod action, which justifies the use thereof in accordance with the invention, has been shown by the experimentally testing as capable to control TLR-induced activation and inflammation on human monocytic cells an peripheral blood monocytic cells. 1. Culture of human monocytes. Peripheral blood mononuclear cells (PBMCs) were obtained by peripheral blood (freshly drawn or buffy coats). Monocytes were then derived from PBMCs by positive selection using anti CD14 paramagnetic beads (Miltenyi Biotec) as described (Marini et al., 2008). Upon purification, cells were shortly cultured (from 24 to 72 hours) in complete culture medium (RPMI 1640 complemented with 10% of fetal bovine serum certified low endotoxin). Some experiments were performed on a human 7 WO 2015/036370 PCT/EP2014/069103 monocytic cell line (MonoMac 6), grown according to the American type culture collection suggestion. 2. Cell treatment with Pidotimod. PBMCs, purified primary human monocytes or MonoMac 6were treated with Pidotimod, at concentrations ranging from 1 to 25 pg/mL and, for different times. In some experiments, after 6 to 48 hours from the beginning of Pidotimod treatment, cells were washed and cultured for 6-24 hours in the presence and absence of TLR 1-9 optimal ligands (Human TLR1-9 Agonist kit, Invivogen). 3. Evaluation of gene expression involved in Pidotimod activity. Upon stimulation, cells were harvested and total RNA was extracted using the RNAeasy mini kit (Qiagen). RNA was then retro-transcribed and subjected to amplification. Real-time PCR was performed using the "Human "RT2 Profiler PCR microarray kit" according to the manufacturer's protocol (SABbiosciences, Qiagen). This kit allows a wide analysis of the expression of genes related to immune activation, giving a particular relevance to the expression of mediators of inflammation. 4. Immunoblot and immunoprecipitation assays. Cell lysates were prepared in lysis buffer containing a protease inhibitor cocktail (Roche). Protein lysates were solved by SDS-PAGE (8%) and transferred to nitrocellulose membranes previously blocked for 1 hour in TBS-Tween 20 (0.1%) containing 5% BSA. To detect the presence of cytoplasmic NLRP12, a first incubation with the goat polyclonal antibody to NLRP12 (Santa Cruz Biotechnology) was followed by the addiction of donkey-anti-goat-HRP secondary antibody. For immunoprecipitation studies, rabbit polyclonal antibodies to NLRP12 (Santa Cruz Biotechnology) were used to precipitate the proteins in the presence of 20pl protein AIG coated beads (protein A/G plus, Santa Cruz Biotechnology) for 12 hours at 4 *C. Protein complexes were washed four to six times, then incubated at 95 *C for 5 minutes and resolved by immunoblot as described above. 5. Transcription array. The Pidotimod ability to reduce the inflammation induced by potent danger signals as LPS or other PAMPs was highlighted by 8 WO 2015/036370 PCT/EP2014/069103 evaluating the level of mRNA specific for effector inflammatory molecules. To this scope total RNA was extracted using the semiautomated extraction system NucliSens Easymag (Biomerieux). RNA was then retro-transcribed in cDNA using the "High capacity cDNA Reverse Transcription Kit" (Applied Biosystem). To perform gene expression studies, cDNA derived from treated or untreated cells was then subjected to PCR using specific Taqman primers-probe sets (Applied Biosystem). Data obtained were analysed using the 2 'c method using Relative Quantification Study software (Applied Biosystems). The Ct values for each gene were normalized to the Ct values for P-actin. 6. ELISA for the quantification of proinflammatory molecules induced by TLR stimulation. The increase of cytokine synthesis is the signal of cellular response to TLR stimulation. Pidotimod disciplines the extent of inflammation by upregulating the expression of NLRP12 which reduces the amplification of inflammatory signals triggered by TLR activation. PBMCs and/or purified monocytes are stimulated or not with an optimal concentration of each TLR ligand upon being pretreated or not with 1-25 pg/mL Pidotimod, and the supernatant of the cell cultures collected after 24 hours from the stimulation onset. The presence of IL-6, IL-8, TNF-a, MCP-1 and IL-10 was quantified in the cultural medium through ELISA assays (Endogen). Results In-vitro studies showed a direct biological activity of Pidotimod on human Monomac 6 cells, and the ability thereof to control an overzealous inflammation response that is detrimental to the host. This has been carried out by in vitro monitoring of the inflammation steps induced by TLRs stimulation and how they are regulated by Pidotimod treatment in terms of cytokine and chemokine release. Further, monitor of pidotimod activity occurs through evaluation of NLRP12 by studying the ability of Pidotimod to increase its transcription and expression following treatment with the compound. 9 WO 2015/036370 PCT/EP2014/069103 Expression of panel of genes associated to the activation of Pattern Recognition Receptor-related pathways was then analyzed by using transcriptional arrays. After 16 hours of treatment, Pidotimod (25pg/ml) was able to induce a significant increase of the NOD-like receptor NLRP12 expression. The two-fold NLRP12 mRNA increase observed in the gene array in Pidotimod-stimulated cells as compared to the unstimulated ones, was confirmed by specific quantitative Real-Time PCR assays. Analysis of cells treated with different concentrations of Pidotimod (25, 5, and 1 pg/ml) at different time points of stimulation (6, 16, 24, and 48 hours of treatment) confirmed this result, showing a peak of increase in NLRP12 expression after 24 hours of stimulation when 25 and 5 pg/ml of the molecule was used (FIGURE 1). Primary monocytes derived from the peripheral blood of healthy donors were also susceptible to this Pidotimod effect. In all the examined samples, purified from 8 different subjects, an increase of NLRP12 mRNA expression, was observed. When compared to non-treated cells, monocytes stimulated with Pidotimod at the concentration of 25 and 5 pg/mlshowed higher levels of NLRP12 mRNA peak within 24 and 48 hours after the beginning of stimulation (FIGURE 2). NLRP12 protein expression followed the course of mRNA expression. Monomac6 were treated for 36 hours with Pidotimod at 5 pg/ml and the NRLP12 expression level was evaluated by immunoblotting upon specific protein immunoprecipitation. A higher amount of NLRP12 protein was detected in sample derived from cells cultured in the presence of Pidotimod when compared to the untreated ones (FIGURE 3). NLRP12 has been defined as a negative regulatory protein that suppresses non canonical NFkB activation and p52-dependent chemokine expression (Allen et al., 2012) and plays a critical role in dampening the potential hazardous proinflammatory activities that are activated by TLR agonists such as microbial products (Williams et al., 2005). Therefore, the effect of Pidotimod was 10 WO 2015/036370 PCT/EP2014/069103 evaluated in primary human monocytes treated with stimuli which, since they act through the TLRs, bring the monocytes to an inflammatory activated phenotype. Pidotimod treatment counteracted the extent of inflammatory mediators induced by TLR agonists. In all the samples evaluated (8 samples derived from 8 different donors), levels of specific MCP-1 consistently diminished, as representatively shown in FIGURE 4. These data were confirmed also when other key proinflammatory molecules were evaluated (IL 6, IL-8 TNF-a and IL-1) showing that Pidotimod controls the production of these mediators at the transcriptional level Data obtained at mRNA level were confirmed by quantification of the inflammatory molecules present in cell supernatants by ELISA. This set of results were also reproducible when total PBMC, instead of purified monocytes, were used. Finally, it has been assessed whether in the context of a stimulation of a representative TLR with its optimal agonist, the pretreatment of cells with Pidotimod controls the NLRP12 downregulation induced in monocytes by TLR stimulation (Williams et al., 2005). Results shown in FIGURE 5 underline how cells cultured in the presence of Pidotimod are able to counteract the decrement of NLRP12 expression both at messenger (left panel) and protein (right panel) level. These data show that Pidotimod is able to upregulate NLRP12 expression in monocytes. Consequently, monocytes respond to NLRP12 activation by downmodulating the production of inflammatory mediators induced by TLR agonists thus controlling excessive or inappropriate inflammation that may be harmful to the host. EXAMPLE 2 A solution to be either injected or sprayed into the nasal cavity having the following wN composition was prepared: 11 WO 2015/036370 PCT/EP2014/069103 1. Pidotimod 6.7% 2. Buffering agents 0.05 % 3. pH adjuster q.s. to pH 6.5 4. Water for injections q.s. to 100 % Preparation: the components 1 to 3 are dissolved in water for injections and mixed until a homogeneous solution is obtained with a pH of 6.5. EXAMPLE 3 A solution for oral administration having the following w/w % composition was prepared: 1. Pidotimod 5.10% 2. Sodium chloride 0.07% 3. Sweetener 0.06% 4. Chelating agents 0.05% 5. Tromethamine 2.50% 6. Preservatives 0.15% 7. Sweeteners solution 31.89% 8. Flavouring agents 0.30% 9. Antioxidants 0.07% 10. Colouring agents 0.01% 11. Purified water 59.80% Preparation In a vessel dissolve the components 1 to 10 in a suitable quantity of purified water. Mix until a clear solution is obtained. Add the remaining quantity of water, mix until a homogeneous solution is obtained and filter. EXAMPLE 4 A tablet for oral administration having the following w/w % composition was prepared: 12 WO 2015/036370 PCT/EP2014/069103 1. Pidotimod 72.70% 2. Diluents 17.65% 3. Disintegrants 4.55% 4. Binders 4.00% 5. Glidants 1.10% Preparation In a vessel mix the components 1 and 2. In another vessel dissolve the component 4 in a suitable quantity of water. Mix until a clear solution is obtained. Spray the obtained solution onto mixed components 1 and 2 until a homogeneous granulate is obtained. After drying, components 3 and 5 are added to the obtained granulate and mixed until a homogeneous mixture is obtained. The mixture is then compressed by means of a tableting machine. EXAMPLE 5 An oil in water cream having the following w/w % composition was prepared: 1. Pidotimod 10.00% 2. Buffering agents 5.40% 3. Chelating agent 0.10% 4. Humectant 5.00% 5. Thickener 0.25% 6. Film former 0.50% 7. Emulsifiers 15.50% 8. Emollients 13.00% 9. Antioxidant 0.50% 10. Preservatives 1.00% 11. Purified Water q.s. to 100.00% Preparation In the main vessel, solubilize components 1, 2, 3, 4, 5 in part of water. Add Xanthan Gum and disperse thoroughly until homogeneity. Separately solubilize 13 WO 2015/036370 PCT/EP2014/069103 component 7 in part of water, then add it to the main vessel while stirring. Heat the phase at 70 - 75 0 C. In another vessel combine the components 8, 9, 10, 11, 12 and heat at 70 - 75 0 C while stirring. Combine the two phases heated at the same temperature and homogenize for about 10 minutes. Cool down to 40* and add on sequence components 13 and 14, homogenizing after each addition. Cool down to room temperature under moderate stirring. EXAMPLE 6 A topical solution having the following w/w % composition was prepared: 1. Pidotimod 10.00% 2. Buffering agents 5.15% 3. Chelating agents 0.10% 4. Humectants 5.00% 5. Film former 1.00% 6. Purified water q.s. to 100.00% Preparation Solubilize components 1, 2, 3, 4, 6 in water. Add component 7 and mix until clear solution is obtained. 14
Claims (18)
1. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof, for use in the treatment of inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway.
2. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 1, characterized in that said diseases are allergic diseases, autoimmune diseases or inflammatory diseases based on mechanisms different from allergic and autoimmune.
3. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 2, characterized in that said allergic diseases are selected from Allergic rhinitis, Allergic conjunctivitis, Atopic allergy, Atopic dermatitis, Contact dermatitis, Eczema and/or Allergic vasculitis.
4. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 2, characterized in that said autoimmune diseases are selected from Alopecia areata, Ankylosing Spondylitis, Autoimmune cardiomyopathy, Autoimmune connective tissue diseases, Autoimmune enteropathy, Autoimmune hepatitis, Autoimmune peripheral neuropathy, Autoimmune pancreatitis, Autoimmune polyendocrine syndrome, Autoimmune thrombocytopenic purpura, Autoimmune urticaria, Autoimmune uveitis, Celiac disease, Chronic Fatigue Syndrome, Cystic fibrosis, Hashimoto's thyroiditis, Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura, IgA nephropathy, Juvenile idiopathic arthritis (or Juvenile rheumatoid arthritis, or Still's disease) Kawasaki's disease, Lichen planus, Lupus erythematosus, Rheumatoid arthritis, Rheumatic fever, Sj6gren's syndrome, Spondyloarthropathy, Temporal arteritis (or giant cell arteritis), Ulcerative colitis, Urticarial vasculitis, Vitiligo. 15 WO 2015/036370 PCT/EP2014/069103
5. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 2, characterized in that said inflammatory diseases based on mechanisms different from allergic and autoimmune are selected from Alzheimer's disease, Atherosclerosis, Chronic Liver Diseases, Chronic Nephropathy, Gastritis, Glomerulonephritis, Hepatitis A B & C, Hydradenitis suppurativa, Hypogammaglobulinemia, Interstitial cystitis, Lichen sclerosus, Liver steatosis, Metabolic Syndrome, Obesity, Parkinson's disease, Pemphigus vulgaris, Post-ischemic inflammation, Psoriasis, Psoriatic arthritis, Raynaud phenomenon, Restless leg syndrome, Retroperitoneal fibrosis, Thrombocytopenia.
6. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to anyone of claims 1 to 5, characterized in that it is administered to a human.
7. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to any of claims 1 to 5, characterized in that it is administered systemically.
8. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 7, characterized in that it is administered by parenteral (intramuscular or intravenous) route or by enteral (oral or rectal) route.
9. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 7, characterized in that it is administered by means of a solid or liquid formulation.
10. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 9, characterized in that said solid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.
11. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 9, characterized in that said liquid 16 WO 2015/036370 PCT/EP2014/069103 formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 0.5% to 20%, more preferably from 1% to 10%, most preferably from 2% to 8%.
12. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 9, characterized in that said solid formulation contains an amount of pidotimod or of a physiologically acceptable salt thereof, from 10 to 1000 mg per single dose, more preferably from 50 to 800 mg per single dose.
13. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to anyone of claims 1 to 5, characterized in that it is administered topically.
14. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 13, characterized in that it is administered by dermal, ocular, auricular, nasal, buccal, intrasinal, endotracheal, vaginal, intravesical, or rectal route.
15. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 13, characterized in that it is administered by means of a solid, semisolid or liquid formulation.
16. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 15, characterized in that said solid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.
17. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to claim 15, characterized in that said semi-solid or liquid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 0.1% to 30%, more preferably from 1 % to 20%, most preferably from 5% to 15%.
18. Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for use according to any of the preceding claims, characterized in 17 WO 2015/036370 PCT/EP2014/069103 that it is administered in combination or in temporal proximity with at least one additional active principle. 18
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPCT/EP2013/068701 | 2013-09-10 | ||
PCT/EP2013/068701 WO2015036009A1 (en) | 2013-09-10 | 2013-09-10 | Pidotimod for use in the treatment of inflammation-associated diseases |
PCT/EP2014/069103 WO2015036370A1 (en) | 2013-09-10 | 2014-09-08 | Pidotimod for use in the treatment of inflammation-associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2014320474A1 true AU2014320474A1 (en) | 2016-03-24 |
Family
ID=49118554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2014320474A Abandoned AU2014320474A1 (en) | 2013-09-10 | 2014-09-08 | Pidotimod for use in the treatment of inflammation-associated diseases |
Country Status (18)
Country | Link |
---|---|
US (1) | US20160213651A1 (en) |
EP (2) | EP3146966A1 (en) |
JP (1) | JP2016529327A (en) |
KR (1) | KR20160052582A (en) |
CN (1) | CN105555267A (en) |
AU (1) | AU2014320474A1 (en) |
CA (1) | CA2922739A1 (en) |
CL (1) | CL2016000543A1 (en) |
EA (1) | EA201690574A1 (en) |
HK (1) | HK1223041A1 (en) |
IL (1) | IL244435A0 (en) |
MD (1) | MD20160040A2 (en) |
MX (1) | MX2016003195A (en) |
PE (1) | PE20160649A1 (en) |
PH (1) | PH12016500472A1 (en) |
SG (1) | SG11201601203TA (en) |
TW (1) | TW201542206A (en) |
WO (2) | WO2015036009A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108003221B (en) * | 2017-12-14 | 2020-08-11 | 北京金城泰尔制药有限公司 | Process for removing pidotimod condensation impurities |
KR102068289B1 (en) | 2018-06-20 | 2020-01-20 | 남희정 | Lens exchangeable glasser |
CN113577242B (en) * | 2021-04-20 | 2023-12-08 | 中山大学附属第五医院 | Application of NLRP12 in preparing medicine for treating coronavirus infection or related inflammatory diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1230706B (en) * | 1989-02-10 | 1991-10-29 | Poli Ind Chimica Spa | DERIVATIVES OF ACID 3 PIROGLUTAMOIL THIAZOLIDIN 4 CARBOXYLIC AND THEIR PHARMACOLOGICAL PROPERTIES. |
IT1231723B (en) | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | PYROGLUTAMIC ACID DERIVATIVES, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
IT1240353B (en) * | 1990-03-30 | 1993-12-07 | Poli Ind Chimica Spa | LIPOSOMAL FORMULATIONS OF IMMUNOMODULATING DRUGS FOR LOCAL AND AEROSOL APPLICATION |
CN1225245C (en) * | 2004-01-16 | 2005-11-02 | 太阳石(唐山)药业有限公司 | Use of Pidotimod in preparation of hepatitis B treating medicine |
EA201591185A1 (en) * | 2012-12-19 | 2016-02-29 | Полихем С.А. | APPLICATION OF PIDOTIMODE FOR THE TREATMENT OF PSORIASIS |
PL2934520T3 (en) * | 2012-12-19 | 2017-08-31 | Polichem Sa | Use of pidotimod to treat atopic dermatitis |
KR20150012167A (en) * | 2013-07-24 | 2015-02-03 | 주식회사 포벨 | Optical module for high speed communication |
-
2013
- 2013-09-10 WO PCT/EP2013/068701 patent/WO2015036009A1/en active Application Filing
-
2014
- 2014-09-03 TW TW103130366A patent/TW201542206A/en unknown
- 2014-09-08 WO PCT/EP2014/069103 patent/WO2015036370A1/en active Application Filing
- 2014-09-08 MX MX2016003195A patent/MX2016003195A/en unknown
- 2014-09-08 AU AU2014320474A patent/AU2014320474A1/en not_active Abandoned
- 2014-09-08 SG SG11201601203TA patent/SG11201601203TA/en unknown
- 2014-09-08 CN CN201480049183.4A patent/CN105555267A/en active Pending
- 2014-09-08 US US14/917,301 patent/US20160213651A1/en not_active Abandoned
- 2014-09-08 PE PE2016000351A patent/PE20160649A1/en not_active Application Discontinuation
- 2014-09-08 MD MDA20160040A patent/MD20160040A2/en not_active Application Discontinuation
- 2014-09-08 EA EA201690574A patent/EA201690574A1/en unknown
- 2014-09-08 JP JP2016541907A patent/JP2016529327A/en active Pending
- 2014-09-08 EP EP16197220.3A patent/EP3146966A1/en not_active Withdrawn
- 2014-09-08 CA CA2922739A patent/CA2922739A1/en not_active Abandoned
- 2014-09-08 KR KR1020167007206A patent/KR20160052582A/en not_active Application Discontinuation
- 2014-09-08 EP EP14761638.7A patent/EP3043796A1/en not_active Withdrawn
-
2016
- 2016-03-03 IL IL244435A patent/IL244435A0/en unknown
- 2016-03-09 CL CL2016000543A patent/CL2016000543A1/en unknown
- 2016-03-10 PH PH12016500472A patent/PH12016500472A1/en unknown
- 2016-09-29 HK HK16111420.9A patent/HK1223041A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201601203TA (en) | 2016-03-30 |
CA2922739A1 (en) | 2015-03-19 |
PH12016500472A1 (en) | 2016-05-16 |
WO2015036370A1 (en) | 2015-03-19 |
EP3146966A1 (en) | 2017-03-29 |
EP3043796A1 (en) | 2016-07-20 |
TW201542206A (en) | 2015-11-16 |
KR20160052582A (en) | 2016-05-12 |
HK1223041A1 (en) | 2017-07-21 |
WO2015036009A1 (en) | 2015-03-19 |
MX2016003195A (en) | 2016-11-14 |
CL2016000543A1 (en) | 2016-11-04 |
US20160213651A1 (en) | 2016-07-28 |
PE20160649A1 (en) | 2016-07-09 |
MD20160040A2 (en) | 2016-07-31 |
EA201690574A1 (en) | 2016-09-30 |
JP2016529327A (en) | 2016-09-23 |
CN105555267A (en) | 2016-05-04 |
IL244435A0 (en) | 2016-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte/macrophage subsets | |
Nachbur et al. | A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production | |
Kalliolias et al. | Interleukin‐27 inhibits human osteoclastogenesis by abrogating RANKL‐mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling | |
Zhou et al. | Circulating monocytes: an appropriate model for bone-related study | |
Wang et al. | The involvement of NLRX1 and NLRP3 in the development of nonalcoholic steatohepatitis in mice | |
EP2950095A1 (en) | Cell-based assay and screening methods for modulators of p75NTR signaling | |
Ye et al. | Decreased interleukin-37 expression in Vogt-Koyanagi-Harada disease and upregulation following immunosuppressive treatment | |
EP3146966A1 (en) | Pidotimod for use in the treatment of inflammation-associated diseases | |
Nie et al. | JNK selective inhibitor, IQ-1S, protects the mice against lipopolysaccharides-induced sepsis | |
Hong et al. | Mas receptor activation attenuates allergic airway inflammation via inhibiting JNK/CCL2-induced macrophage recruitment | |
Sarver et al. | FAM19A (TAFA): An emerging family of neurokines with diverse functions in the central and peripheral nervous system | |
Repa et al. | Dysregulated production of interleukin-1β upon activation of the NLRP3 inflammasome in patients with familial Mediterranean fever | |
He et al. | Decreased expression of A20 is associated with ocular Behcet’s disease (BD) but not with Vogt-Koyanagi-Harada (VKH) disease | |
Nie et al. | Myricetin ameliorates experimental autoimmune myocarditis in mice by modulating immune response and inhibiting MCP-1 expression | |
CA3124730A1 (en) | Small rna medicament for prevention and treatment of inflammation-related diseases and combinations thereof | |
Wu et al. | Ribosome-rescuer PELO catalyzes the oligomeric assembly of NOD-like receptor family proteins via activating their ATPase enzymatic activity | |
Gong et al. | Glycyrrhizic acid inhibits myeloid differentiation of hematopoietic stem cells by binding S100 calcium binding protein A8 to improve cognition in aged mice | |
JP2010537952A (en) | Regulators of hypersensitivity reactions | |
JP2002535286A (en) | Method for treating multiple sclerosis with chaperonin 10 and β-interferon | |
Wu et al. | Unfolded protein response factor ATF6 augments T helper cell responses and promotes mixed granulocytic airway inflammation | |
KR20210147411A (en) | Use of RORα for cancer treatment through immune cell activation | |
CN101821393A (en) | T-cell cytokine-inducing surface molecules and methods of use | |
Bunya et al. | Tolerability of topical tocilizumab eyedrops in dogs: A pilot study | |
US11571462B2 (en) | Engineered CCL20 locked dimer polypeptide | |
Tsukidate et al. | N-Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |